Trial · NCT06743503
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
NCT06743503, Phase 1, Recruiting, Nanjing IASO Biotechnology Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies. Trials, record NCT06743503. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06743503
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
- NCT number
- NCT06743503
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Conditions
- Large B-cell Lymphoma
- Interventions
- UB-VV400, Rapamycin
- First posted
- 2024-12-20
- Last updated
- 2025-09-18
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with adverse events as assessed by CTCAE v5.0 | up to 24 months | Type, frequency, and severity of adverse events (AEs) and laboratory abnormalities |
| Primary | Maximum tolerated dose (MTD) or maximum administered dose (MAD) of UB-VV400 alone and in combination with rapamycin. | up to 24 months | |
| Secondary | Objective response rate (ORR) per the Investigator using the Lugano 2014 criteria. | up to 24 months | |
| Other | Quantification of Immune cell subset frequencies (T/B/NK cells) | up to 24 months | |
| Other | Complete response (CR) rate, as determined by the Investigator using the Lugano 2014 criteria. | up to 24 months | |
| Other | Durability of response (DOR), the duration of response for subjects who acheived PR and CR as determined by the Investigator using the Lugano 2014 criteria. | up to 24 months | |
| Other | Progression-free survival (PFS) and Overall survival (OS). | up to 24 months | |
| Other | Quantification of plasma cytokines. | up to 24 months | |
| Other | Detection of integrated UB-VV400 transgene sequence and expression of CAR in peripheral blood. | up to 24 months | |
| Other | Maximum concentration (Cmax) of UB-VV400 particle and CAR-T cells. | up to 24 months |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06743503
GET https://conductscience.org/api/trials/v1/NCT06743503/registered